Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Expenses (2018 - 2025)

Bicycle Therapeutics' Operating Expenses history spans 8 years, with the latest figure at $72.7 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 1.81% year-over-year to $72.7 million; the TTM value through Dec 2025 reached $319.7 million, up 30.39%, while the annual FY2025 figure was $319.7 million, 30.39% up from the prior year.
  • Operating Expenses reached $72.7 million in Q4 2025 per BCYC's latest filing, down from $77.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $89.5 million in Q2 2025 to a low of $17.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $49.5 million, with a median of $52.9 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: soared 76.08% in 2022, then grew 1.81% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $21.8 million in 2021, then skyrocketed by 62.4% to $35.4 million in 2022, then skyrocketed by 68.28% to $59.6 million in 2023, then grew by 19.82% to $71.4 million in 2024, then rose by 1.81% to $72.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Operating Expenses are $72.7 million (Q4 2025), $77.3 million (Q3 2025), and $89.5 million (Q2 2025).